Stealth Biotherapeutics announced top-line data from the Phase 3 MMPOWER-3 trial evaluating elamipretide for the treatment of patients with Primary Mitochondrial Myopathy (PMM). The study did not meet its primary endpoints assessing changes in the six-minute walk...